Discover our initiatives in various therapeutic areas
Fulvestrant SPC® is used either:
– Alone, to treat postmenopausal women with a type
of breast cancer called estrogen receptor positive
breast cancer that is locally advanced or has spread
to other parts of the body (metastatic), or
– In combination with palbociclib to treat women with
a type of breast cancer called hormone receptor positive, humanepidermal growth factor receptor 2- negative breast cancer, that is locallyadvanced or has spread to other parts of the body (metastatic). Womenwho have not reached menopause will also be treated with a medicinecalled a luteinizing hormone releasing hormone (LHRH) agonist.
Strength:
250 mg/5 ml
Dosage Form:
Pre-filled syringe
Active ingredient:
Fulvestrant
Docetaxel SPC® is used for:
Advanced breast cancer: Docetaxel SPC could be administered either alone or
in combination with doxorubicin, or trastuzumab, or capecitabine.
Early breast cancer: with or without lymph node involvement, Docetaxel SPC
could be administered in combination with doxorubicin and cyclophosphamide.
Strength:
80 mg/4ml
Dosage Form:
Vial for injection
Active ingredient:
Docetaxel